Translational strategy
Translational strategy
Activities at the ARTORG Center span the arc from basic research enquiry into biomedical engineering domains to clinical introduction of novel technologies and procedures.
Translation into clinical care means fundamental changes in the way disruptive technology is deployed to deliver better diagnostic, therapeutic, rehabilitation and chronic condition management outcomes. Projects at the ARTORG are designed and pursued to achieve the goal of clinical translation.
Since its founding more than 10 years ago, the ARTORG Center has built a track record of successful commercial exploitation of innovative research results. A number of University of Bern spin-offs have acquired rights to technology intellectual property, including patents, know-how, models and clinical data. These companies have matured into commercial success, attracting researchers from the ARTORG and Inselspital, investors and high-caliber management teams and becoming revenue positive with CE/FDA approved Medtech products now found in hospitals across the globe. The ARTORG Center places great emphasis on supporting a sustainable pipeline of commercial venturing activities, from spin-offs to licensing and partnering.
ARTORG Spin-offs:
- Alveolix AG, Lung-on-a-chip
- CAScination AG, Image-guided and robotic surgery for precision medicine applications
- LEM Surgical, Next generation robotics
- PeriVision SA, Helping Eye Doctors Save Vision with AI, VR and the cloud
- RetinAI AG, Deep learning for big data use in therapeutic decision making
- SurgeonsLab, 4D simulation for microsurgical training and intervention planning
- URODEA, The first non-invasive solution against urinary retention